Abecma (idecabtagene vicleucel)

Numéro de dossier de l’APP: 21655

État des négociations:

Négociation envisagée

Indication(s):

For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment

Promoteur/fabricant:

Celgene Inc.

Numéro de projet de l’ACMTS:

PG0240

Lettre-contrat de l’APP:

Sans objet

Conclusion du processus de négociation:

Sans objet